PCMH
SMMT icon

Polymer Capital Management (HK)’s Summit Therapeutics SMMT Stock Holding History

Polymer Capital Management (HK)’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Buy
224,853
+91,819
+69% +$1.63M 0.17% 66
2026
Q1 		$2.52M Sell
133,034
-1,288,121
-91% -$20.8M 0.22% 65
2025
Q4 		$24.9M Buy
1,421,155
+603,879
+74% +$11.4M 3.54% 8
2025
Q3 		$16.9M Sell
817,276
-72,753
-8% -$1.76M 2.33% 10
2025
Q2 		$18.9M Buy
890,029
+493,854
+125% +$11.3M 2.86% 6
2025
Q1 		$7.64M Buy
396,175
+176,355
+80% +$3.54M 1.3% 26
2024
Q4 		$3.92M Buy
+219,820
New +$4.26M 0.68% 42

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Polymer Capital Management (HK)'s SMMT Position: Q2 2026 in Review

Polymer Capital Management (HK) increased its Summit Therapeutics (SMMT) stake by 69% in Q2 2026, buying an estimated $1.63M and bringing the position to 224,853 shares worth $3.28M. The position accounts for 0.17% of the portfolio, ranked #66.

Polymer Capital Management (HK) first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $24.9M in Q4 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Polymer Capital Management (HK) held 224,853 shares of Summit Therapeutics worth $3.28M as of Q2 2026.
  • Polymer Capital Management (HK) bought 91,819 Summit Therapeutics shares in Q2 2026, an estimated $1.63M.
  • Summit Therapeutics made up 0.17% of Polymer Capital Management (HK)'s portfolio in Q2 2026, its #66 holding.
  • Polymer Capital Management (HK) first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Polymer Capital Management (HK)'s Summit Therapeutics position peaked at $24.9M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Polymer Capital Management (HK)'s 13F filing for Q2 2026, filed 13 Aug 2026.